Screening for Colorectal Cancer: US Preventive Services Task Force Recommendation Statement.

IMPORTANCE Colorectal cancer is the second leading cause of cancer death in the United States. In 2016, an estimated 134,000 persons will be diagnosed with the disease, and about 49,000 will die from it. Colorectal cancer is most frequently diagnosed among adults aged 65 to 74 years; the median age at death from colorectal cancer is 68 years. OBJECTIVE To update the 2008 US Preventive Services Task Force (USPSTF) recommendation on screening for colorectal cancer. EVIDENCE REVIEW The USPSTF reviewed the evidence on the effectiveness of screening with colonoscopy, flexible sigmoidoscopy, computed tomography colonography, the guaiac-based fecal occult blood test, the fecal immunochemical test, the multitargeted stool DNA test, and the methylated SEPT9 DNA test in reducing the incidence of and mortality from colorectal cancer or all-cause mortality; the harms of these screening tests; and the test performance characteristics of these tests for detecting adenomatous polyps, advanced adenomas based on size, or both, as well as colorectal cancer. The USPSTF also commissioned a comparative modeling study to provide information on optimal starting and stopping ages and screening intervals across the different available screening methods. FINDINGS The USPSTF concludes with high certainty that screening for colorectal cancer in average-risk, asymptomatic adults aged 50 to 75 years is of substantial net benefit. Multiple screening strategies are available to choose from, with different levels of evidence to support their effectiveness, as well as unique advantages and limitations, although there are no empirical data to demonstrate that any of the reviewed strategies provide a greater net benefit. Screening for colorectal cancer is a substantially underused preventive health strategy in the United States. CONCLUSIONS AND RECOMMENDATIONS The USPSTF recommends screening for colorectal cancer starting at age 50 years and continuing until age 75 years (A recommendation). The decision to screen for colorectal cancer in adults aged 76 to 85 years should be an individual one, taking into account the patient's overall health and prior screening history (C recommendation).

[1]  C. Flowers,et al.  Colorectal cancer screening for average‐risk adults: 2018 guideline update from the American Cancer Society , 2018, CA: a cancer journal for clinicians.

[2]  E. Feuer,et al.  SEER Cancer Statistics Review, 1975-2003 , 2006 .

[3]  Joseph A Hill United States Life Tables , 2013 .

[4]  Jennifer S Lin,et al.  Screening for Colorectal Cancer: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force. , 2016, JAMA.

[5]  A. Zauber,et al.  Understanding the contribution of family history to colorectal cancer risk and its clinical implications: A state‐of‐the‐science review , 2016, Cancer.

[6]  Eric J Feuer,et al.  Secular trends in colon and rectal cancer relative survival. , 2013, Journal of the National Cancer Institute.

[7]  S. Hendren,et al.  Colorectal cancer outcomes and treatment patterns in patients too young for average‐risk screening , 2016, Cancer.

[8]  G. Cooper,et al.  Racial disparities in the use of and indications for colorectal procedures in Medicare beneficiaries , 2004, Cancer.

[9]  B. Larsen [Colorectal cancer screening]. , 2010, Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke.

[10]  D. Ahlquist,et al.  Stool DNA Testing for Screening Detection of Colorectal Neoplasia in Alaska Native People. , 2016, Mayo Clinic proceedings.

[11]  A. Jemal,et al.  Colorectal cancer statistics, 2017 , 2017, CA: a cancer journal for clinicians.

[12]  Á. Lanas,et al.  Vorsorge des kolorektalen Karzinoms: Koloskopie oder immunologischer Stuhltest , 2013, Zeitschrift für Gastroenterologie.

[13]  Reiko Nishihara,et al.  Long-term colorectal-cancer incidence and mortality after lower endoscopy. , 2013, The New England journal of medicine.

[14]  Á. Lanas,et al.  Colonoscopy versus fecal immunochemical testing in colorectal-cancer screening. , 2012, The New England journal of medicine.

[15]  T. Wilt,et al.  Screening for cancer: advice for high-value care from the American College of Physicians. , 2015, Annals of internal medicine.

[16]  O. Dominic,et al.  American College of Gastroenterology Guidelines for Colorectal Cancer Screening 2008 , 2009, The American Journal of Gastroenterology.

[17]  Ruth Etzioni,et al.  Personalizing age of cancer screening cessation based on comorbid conditions: model estimates of harms and benefits. , 2014, Annals of internal medicine.

[18]  R. Nelson,et al.  Colorectal , 1994, Current opinion in general surgery.

[19]  D. Wickerham,et al.  Outcomes among African-Americans and Caucasians in colon cancer adjuvant therapy trials: findings from the National Surgical Adjuvant Breast and Bowel Project. , 1999, Journal of the National Cancer Institute.

[20]  S. Chiou,et al.  Effectiveness of fecal immunochemical testing in reducing colorectal cancer mortality from the One Million Taiwanese Screening Program , 2015, Cancer.

[21]  M. Hernán,et al.  The NordICC Study: Rationale and design of a randomized trial on colonoscopy screening for colorectal cancer , 2012, Endoscopy.

[22]  J. Faivre,et al.  Reduction in colorectal cancer mortality by fecal occult blood screening in a French controlled study. , 2004, Gastroenterology.

[23]  C. Klabunde,et al.  Vital Signs: Colorectal Cancer Screening Test Use — United States, 2012 , 2013, MMWR. Morbidity and mortality weekly report.

[24]  O. Kronborg,et al.  Randomized study of biennial screening with a faecal occult blood test: results after nine screening rounds , 2004, Scandinavian journal of gastroenterology.

[25]  Karen M Kuntz,et al.  Estimation of Benefits, Burden, and Harms of Colorectal Cancer Screening Strategies: Modeling Study for the US Preventive Services Task Force. , 2016, JAMA.

[26]  J. Willis,et al.  Performance of multitarget stool DNA testing in African American patients , 2018, Cancer.

[27]  M. Tonelli,et al.  Recommendations on screening for colorectal cancer in primary care , 2016, Canadian Medical Association Journal.

[28]  Douglas K Rex,et al.  Corrigendum: American College of Gastroenterology Guidelines for Colorectal Cancer Screening 2008 , 2009, The American Journal of Gastroenterology.

[29]  Philip S Rosenberg,et al.  Colorectal Cancer Incidence Patterns in the United States, 1974–2013 , 2017, Journal of the National Cancer Institute.

[30]  Elizabeth M Webber,et al.  Family history and the natural history of colorectal cancer: systematic review , 2015, Genetics in Medicine.

[31]  David Lieberman,et al.  Colorectal Cancer Screening: Recommendations for Physicians and Patients From the U.S. Multi-Society Task Force on Colorectal Cancer. , 2017, Gastroenterology.

[32]  M. Bretthauer,et al.  Effectiveness of Screening Colonoscopy to Prevent Colorectal Cancer Among Medicare Beneficiaries Aged 70 to 79 Years , 2016, Annals of Internal Medicine.

[33]  M. Hernán,et al.  Effect of flexible sigmoidoscopy screening on colorectal cancer incidence and mortality: a randomized clinical trial. , 2014, JAMA.

[34]  W. Baine,et al.  The Agency for Healthcare Research and Quality , 2006, Italian Journal of Public Health.

[35]  B. Levin,et al.  Screening and surveillance for the early detection of colorectal cancer and adenomatous polyps, 2008: a joint guideline from the American Cancer Society, the US Multi-Society Task Force on Colorectal Cancer, and the American College of Radiology. , 2008, Gastroenterology.

[36]  C M Mangham,et al.  Nottingham trial of faecal occult blood testing for colorectal cancer: a 20-year follow-up , 2011, Gut.

[37]  Angela Fagerlin,et al.  Adherence to colorectal cancer screening: a randomized clinical trial of competing strategies. , 2012, Archives of internal medicine.

[38]  O. Brawley Colorectal cancer control: providing adequate care to those who need it. , 2014, Journal of the National Cancer Institute.

[39]  D. Ransohoff,et al.  Multitarget stool DNA testing for colorectal-cancer screening. , 2014, The New England journal of medicine.

[40]  B. Levin,et al.  Colorectal cancer screening. Clinical practice guidelines in oncology. , 2013, Journal of the National Comprehensive Cancer Network : JNCCN.

[41]  Chyke A Doubeni,et al.  Racial Disparities in Colorectal Cancer Survival: Is Elimination of Variation in Care the Cure? , 2015, Journal of the National Cancer Institute.

[42]  L. Seeff,et al.  Patterns of Colorectal Cancer Test Use, Including CT Colonography, in the 2010 National Health Interview Survey , 2012, Cancer Epidemiology, Biomarkers & Prevention.

[43]  Thomas Rösch,et al.  Prospective evaluation of methylated SEPT9 in plasma for detection of asymptomatic colorectal cancer , 2013, Gut.

[44]  Kirsten Bibbins-Domingo,et al.  Aspirin Use for the Primary Prevention of Cardiovascular Disease and Colorectal Cancer: U.S. Preventive Services Task Force Recommendation Statement. , 2016, Annals of internal medicine.

[45]  Bernadette Mazurek Melnyk,et al.  Screening for colorectal cancer: U.S. Preventive Services Task Force recommendation statement. , 2008, Annals of internal medicine.